Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study
Diagnostics · 23.03.2026 · 16 (6) · 958
DOI: 10.3390/diagnostics16060958 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Diagnostics, online erschienen am 23.03.2026. Verfasst von Mert Gebes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Research Council of Turkey, Scientific and Technological Research Council of Türkiye (TÜBİTAK), 2209-A University Students Research Projects Support Program.
Abstract (Originalsprache)
Background/Objectives: Post-COVID-19 fibrotic-like lung changes (PC19-FLC), which may represent persistent post-inflammatory abnormalities or early fibrotic remodeling, have emerged as an important long-term pulmonary sequela following SARS-CoV-2 infection. However, the underlying pathogenic mechanisms remain incompletely understood. This study aimed to investigate the potential association between mammalian target of rapamycin (mTOR) activity and the presence of PC19-FLC.
Methods
This single-center, cross-sectional study included 70 patients who met the predefined inclusion criteria. Participants were categorized according to the presence or absence of PC19-FLC on chest computed tomography. Demographic, laboratory, and radiological data were collected. Serum mTOR levels were measured using enzyme-linked immunosorbent assay (ELISA).
Results
Serum mTOR levels and modified Medical Research Council (mMRC) dyspnea scores were significantly higher in patients with PC19-FLC compared with those without fibrotic-like changes. Receiver operating characteristic (ROC) curve analysis identified a serum mTOR cut-off value of 6.15 ng/mL (sensitivity 83%, specificity 94%) for discriminating patients with PC19-FLC in this cohort. Serum mTOR levels were significantly correlated with forced vital capacity (FVC%), mMRC dyspnea score, and peripheral oxygen saturation (SpO2).
Conclusions
Increased serum mTOR levels were associated with the presence of fibrotic-like lung changes after COVID-19 and may help distinguish patients with such CT abnormalities in this cohort. Higher mTOR levels were also associated with greater dyspnea severity, lower lung volumes, and reduced peripheral oxygen saturation. These findings suggest a potential role of mTOR signaling in post-COVID-19 pulmonary sequelae and warrant further investigation in larger, multicenter studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Türkiye.
- Faculty of Medicine, Department of Pulmonology, Mugla Sitki Kocman University, Mugla 48000, Türkiye.
- Faculty of Medicine, Department of Medical Biology, Mugla Sitki Kocman University, Mugla 48000, Türkiye.
- Faculty of Medicine, Department of Radiology, Mugla Sitki Kocman University, Mugla 48000, Türkiye.
ORCID-Profile: Ozge Oral Tapan, Tuba Edgunlu
Förderung
- Scientific and Technological Research Council of Turkey
- Scientific and Technological Research Council of Türkiye (TÜBİTAK), 2209-A University Students Research Projects Support Program
Zitieren
APA
Gebes, M., Oral Tapan, O., Edgunlu, T., & Dogan, E. (2026). Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study. Diagnostics, 16(6), 958. https://doi.org/10.3390/diagnostics16060958
Vancouver
Gebes M, Oral Tapan O, Edgunlu T, Dogan E. Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study. Diagnostics. 2026;16(6):958. doi:10.3390/diagnostics16060958
BibTeX
@article{Gebes2026,
author = {Gebes, Mert and Oral Tapan, Ozge and Edgunlu, Tuba and Dogan, Emrah},
title = {Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {6},
pages = {958},
doi = {10.3390/diagnostics16060958}
}
EUVIMED